Therapeutic Asset Ratings
368 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
BOLD-100
Pancreatic Neoplasm
Bold Therapeutics, Inc.
P1/2
CC
(40)
Camizestrant
Pancreatic Neoplasm
AstraZeneca
P1/2
CC
(40)
Claudin18.2 Car-T Cells
Pancreatic Neoplasm
Essen Biotech
P1/2
CC
(40)
cts2190 capsules
Pancreatic Neoplasm
CytosinLab Therapeutics Co., Ltd.
P1/2
CC
(40)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301)
Pancreatic Neoplasm
Washington University School of Medicine
P1/2
CC
(40)
Datopotamab Deruxtecan
Pancreatic Neoplasm
AstraZeneca
P1/2
CC
(40)
Domvanalimab
Pancreatic Neoplasm
James Cleary, MD, PhD
P1/2
CC
(40)
Egfr Fpbmc
Pancreatic Neoplasm
University of Virginia
P1/2
CC
(40)
Fmc-376
Pancreatic Neoplasm
Frontier Medicines Corporation
P1/2
CC
(40)
gi-108
Pancreatic Neoplasm
GI Innovation, Inc.
P1/2
CC
(40)
il-15 enhanced engineered nk cells
Pancreatic Neoplasm
M.D. Anderson Cancer Center
P1/2
CC
(40)
Immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (SFTPJ, surfactant associated protein J) isoform 2, extracellular domain 1 (EC1)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.9%) L123>T (113), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [VKAPPA (Homo sapiens IGKV4-1*01 (91.1%) - IGKJ4*01 (100%), CDR-IMGT [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, glycoform alfa
Pancreatic Neoplasm
Suzhou Transcenta Therapeutics Co., Ltd.
P1/2
CC
(40)
jmt203
Pancreatic Neoplasm
Shanghai JMT-Bio Inc.
P1/2
CC
(40)
js007
Pancreatic Neoplasm
Fudan University
P1/2
CC
(40)
js015
Pancreatic Neoplasm
Fudan University
P1/2
CC
(40)
kn046
Pancreatic Neoplasm
InxMed (Shanghai) Co., Ltd.
P1/2
CC
(40)
Kras Neoantigen Nanovaccine
Pancreatic Neoplasm
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
P1/2
CC
(40)
mdx2001
Pancreatic Neoplasm
ModeX Therapeutics, An OPKO Health Company
P1/2
CC
(40)
Mesothelin-Directed Car-T Cells
Pancreatic Cancer
Essen Biotech
P1/2
CC
(40)
Mkrasvax
Pancreatic Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1/2
CC
(40)
Mutant Kras G12V-Specific Tcr Transduced Autologous T Cells
Pancreatic Neoplasm
Changhai Hospital
P1/2
CC
(40)
Narmafotinib
Pancreatic Neoplasm
Amplia Therapeutics Limited
P1/2
CC
(40)
Neoantigen Specific Tcr-T Cell Drug Product
Pancreatic Neoplasm
Alaunos Therapeutics
P1/2
CC
(40)
Nuv-1511
Pancreatic Neoplasm
Nuvation Bio Inc.
P1/2
CC
(40)
Odm-212
Pancreatic Neoplasm
Orion Corporation, Orion Pharma
P1/2
CC
(40)
Showing 176 to 200 of 368 assets
Previous
Page 8 of 15
Next
